Journal of Clinical & Medical Case Reports
Review Article
Emerging Antibiotic Resistance in Post-COVID-19 Co-infections
Sibi Das1*, Sethi Das C2, Jibin VG3 and Silvanose CD4
1Sri Siddhartha Medical College, Tumkuru, Karnataka, India
2Aster CMI Hospital, Bengaluru, India
3District Hospital, Bundi, Rajasthan, India
4Dubai Falcon Hospital, Dubai, UAE
Address for Correspondence:
Das S, Sri Siddhartha Medical College, Tumkuru, Karnataka,
India; E-mail: sdsilvanose@gmail.com
Submission: 22 February, 2023
Accepted: 23 March, 2023
Published: 28 March, 2023
Copyright: © 2023 Sibi D, et al. This is an open access article
distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Abstract
There is emerging evidence of antibiotic resistance, particularly
for antibiotics commonly used to treat secondary bacterial infections
in COVID-19 patients. The overuse of antibiotics in COVID-19 patients
has contributed to the development of antibiotic-resistant bacterial
strains against amoxicillin, azithromycin, cephalosporins, ciprofloxacin,
and carbapenem. The most resistant bacteria isolated from COVID-19
patients include Klebsiella pneumonia, Acinetobacter baumannii,
and Pseudomonas aeruginosa, which showed multiple antibiotic
resistance. The increasing rates of antibiotic resistance are labeled as
a “silent pandemic” as post covid-19 bacterial infections caused by
deadly pathogens are the most significant threats to global health.